Using a new radiation technique to treat brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II, single-arm, multi-center study evaluates the feasibility and tolerance of whole-brain radiation therapy (WBRT) using an upfront pulsed reduced dose-rate (PRDR) technique for patients with solid tumor brain metastases. Participants will receive a total dose of 30 Gy in 10 fractions of PRDR WBRT within 14 days of registration, along with memantine to assess its impact on neurocognitive decline compared to historical controls. The study aims to enroll 53 adult patients and includes an interim analysis after the first 27 patients to determine feasibility and preliminary outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years at diagnosis of brain metastases.
2. Eastern Cooperative Oncology Group (ECOG) Performance Score of \<2.
3. Participants must have a biopsy-proven solid malignancy (histologic proof or unequivocal cytologic proof solid tumor malignancy from either the primary or any metastatic site) with intracranial lesions radiographically consistent with or pathologically proven to be brain metastases.
4. Patients who have undergone prior systemic therapy are eligible.
5. Life expectancy from extracranial disease greater than six months.
6. Patients with measurable brain metastasis.
7. Patients may have had prior therapy for brain metastasis, including stereotactic radiosurgery (SRS)and surgical resection. Patients must have completed prior therapy by at least 7 days prior to study enrollment for SRS and at least 14 days for surgical resection
8. If an open biopsy is performed, the patient must be at least one-week post-biopsy. This requirement is not necessary for stereotactic biopsies.
9. Creatinine clearance is ≥ 30 mL/min.
10. Start of PRDR WBRT within two weeks following registration.
11. Ability to complete the Neurocognitive Function (NCF) test battery (including people whose primary language is English).
12. Patients with previous or other malignancies whose disease is controlled and not impacting ECOG performance or life expectancy.
13. Willing and able to give consent and to comply with treatment and follow-up schedule.

Exclusion Criteria:

1. Metastases from hematological malignancy, or central nervous system malignancy.
2. Patients whose malignancy is being treated with curative intent.
3. Leptomeningeal metastases.
4. Contraindication to MRI imaging with contrast.
5. Contraindication to memantine including concurrent use of N-methyl-D-aspartate (NMDA) antagonists.
6. Stage IV-V chronic kidney disease or end-stage renal disease.
7. Participants with a maximum tumor diameter exceeding 5 cm (if not resected).
8. Prior cranial whole brain radiation therapy.
9. Past medical history of dementia which is thought to be unrelated to the brain metastases.
10. Women of childbearing potential who are known to be pregnant or are unwilling to use an acceptable method of contraception from the time of informed consent until completion of the course of radiotherapy.
11. Patients must not have a serious medical or psychiatric illness that would, in the opinion of the treating physician, prevent informed consent or completion of protocol treatment, and/or follow-up visits.
12. Non-native English speakers will be excluded since patients often lose their faculty with the language they acquired second before their native language is affected in the context of cognitive decline. This could adversely affect performance on verbal cognitive tasks.

Where it's running

• Froedtert Hospital & the Medical College of Wisconsin
  Milwaukee, Wisconsin, United States Recruiting
• Clement J. Zablocki Veterans Affairs Medical Center
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Lindsay Puckett, MD — Medical College of Wisconsin
• Study coordinator: Medical College of Wisconsin Cancer Center Clinical Trials Office
• Email: cccto@mcw.edu
• Phone: 866-680-0505

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EarlyFDG PET after Radiotherapy to See Brain Metastases and Radionecrosis

  This study tests whether a short FDG-PET scan after radiotherapy can help tell apart radionecrosis from recurring brain metastases in adults.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07632092

• IL-8 receptor–modified CAR T cells for brain metastases in adults

  This phase 1 study tests whether patient-derived, IL-8 receptor–modified CD70 CAR T cells can be safely given to adults with brain metastases.

  Recruiting Phase 1 University of Florida · Gainesville, Florida · NCT07569263

• Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain

  This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Chongqing, Chongqing Municipality and 2 other locations · NCT07481786

• Molecular comparison of primary gastroesophageal cancers and their brain metastases

  This project will test whether key biomarkers (HER2, MSI, PD-L1, CLDN18.2) match between primary gastroesophageal tumors and their matched brain metastases using archived tissue.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07464470

• Imaging inflammation in primary and metastatic brain tumors with [C-11]-CS1P1 PET

  This trial will test a new PET tracer, [C-11]-CS1P1, in adults with primary or secondary brain tumors to see if tracer patterns of inflammation relate to MRI, treatments, and clinical outcomes.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07462507

• Cognitive stepped care program for adults with brain metastases

  This project will test whether routine screening plus a stepped program of education and tailored cognitive support can help adults with brain metastases manage thinking and memory problems.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07355348

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.